echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 751 drugs that passed medicare form reviews, but caused controversy?

    751 drugs that passed medicare form reviews, but caused controversy?

    • Last Update: 2020-10-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Text . . . On September 18, the State Administration of Health Insurance announced the "2020 National Health Insurance Drug Catalog Adjustment through the form review of the list of declared drugs", according to statistics, the release of the form of examination of about 751 kinds of drugs (due to meet the different declaration situation, some varieties are duplicated).
    involved 573 kinds of chemical drugs and 178 kinds of Chinese medicine.
    Among them, there are 18 products in the health insurance catalogue, mainly for the re-determination of payment standards and the expansion of the varieties of adaptation certificates at the end of the agreement;
    the 2020 National Health Insurance Drug Catalog adjustment into the list of drug conditions and the number of drugs list is full of points, "GV-971" into health insurance is appropriate? The National Health Insurance Administration released the 2020 medical insurance list of the first review list, look at a full point: this time through the form of the drug list, before December 31, 2019, into the five (including) or more provincial version of the latest version of the list of essential health insurance drugs 493 drugs, accounting for two-thirds of the list of drugs reviewed, the largest category of drugs included; The most representative and hot varieties of innovative drugs belong to PD-1/PDL-1, this time there are 7 included in the list, in addition to the inclusion of health insurance Dabershu, currently listed in China all PD-1/PDL/1 finalists;
    GV-971 China's independent research and development and has independent intellectual property rights of innovative drugs, is the world's major pharmaceutical companies to invest hundreds of billions of dollars in research and development have failed, the world for 17 years without the approval of new drugs with Alzheimer's disease background, China's national drug regulator Bureau conditions approved the listing of the drug, but triggered the netizens on the drug "reliable" question, is now in the medical insurance directory of the first instance list, once again triggered a heated discussion of netizens, can not help but ask, GV-971 into the health insurance is appropriate? In fact, GV-971 can be included in health insurance from two different perspectives: on the one hand, GV-971 for the country's new batch of fully autonomous, the world's first innovative drugs, from the protection of enterprises' enthusiasm for innovative drug development, encourage innovation, GV-971 is fully qualified to be included in health insurance, and the global Alzheimer's patients are looking forward to more effective treatment of Alzheimer's disease.
    On the other hand, the approval of GV-971 listing by many experts questioned, the capital medical university president, former Peking University School of Life Sciences Dean Rao Yi has issued a paper questioning the GV-971 "utility problem", that "GV-971" "multi-target" utility is exaggerated suspicion.
    also noted that "GV-971" research team Geng Meiyu has previously published 12 papers related to or closely related to "GV-971", however, Geng Meiyu and his team in the 2019 release of "GV-971" paper did not cite any of them.
    In this case, the premature inclusion of GV-971 in health insurance is worth discussing, after all, GV-971 listing is the State Drug Administration "conditional approval", "conditional" is that the State Drug Administration requires applicants to continue the pharmacological mechanism research and long-term safety, ability to study, improve the analysis method of oligosaccharin, timely submission of relevant test data, if no further data support, then the drug approval will be withdrawn.
    also means that the clinical effects of the drug need to be further 100% effective verification, if the clinical response of the drug later is good, the elimination of "conditional" approval and then included in health insurance, should be the most secure way.
    focus on monitoring the inclusion of complementary medications and OTC, is there a violation of the previous rules? On July 31 this year, article 36 of the Interim Measures for the Administration of Drug Use in Basic Medical Insurance issued by the State Administration of Health Insurance clearly stipulates that, in principle, no new OTC drugs will be added to the Drug Catalog.
    however, there are still a lot of OTC varieties included in the list, such as: fennel positive gas adhesive, ox yellow clear sense capsules, nasal tablets, nasal drips and other drugs.
    In addition to the dynamic adjustment of health insurance drugs, in the transfer of drugs, the key monitoring list of drugs are the focus of attention, the form of examination through the list also has auxiliary drugs and key monitoring drugs, as well as 2019 was kicked out of health insurance drugs, the list is very complex, which led to controversy among netizens, asking "is it contrary to the previous principles?" At the same time, some industry experts pointed out that this transfer list meets the fifth condition of the drug Idara feng rightol injection with a strong solution and Idala feng sodium chloride injection, although Idala fon right ol injection with a thick solution for chemical 1 Class, belongs to the innovative drug category, but the main active ingredient of the two drugs of the Idala fon rightol injection with a thick solution and the sodium chloride injection of Idala, while the Idarafeng injection is a key monitoring, in theory should not be included in the health insurance catalogue.
    Also experts pointed out that the Idala rightol injection with a thick solution and Idala sodium chloride injection although the main ingredient is Idala, but a drug into the health insurance form review list or included in the health insurance list, is a single drug variety through the health insurance form review or health insurance review after inclusion, rather than looking at a variety of the main ingredients.
    Idala is a class 1 chemical drug with a strong solution for rightol injection, the exclusive variety of the first sound pharmaceutical industry, and is approved for listing in accordance with the priority review and special review, indicating that the drug meets the clinical urgent needs of the drug, while complying with Between 1 January 2015 and 31 December 2019, there is no problem in listing drugs (including new active ingredients and new dosage forms) approved by the State Drug Administration in accordance with the application procedure for the registration of new drugs.
    In addition, Idala sodium chloride injections are approved for listing in accordance with the new chemical drug registration classification 3 categories, although Idala feng is included in the list of auxiliary drugs and key monitoring drugs, but Ida la sodium chloride injections approved for the listing of fewer enterprises, currently only Jiangsu Zhengda Fenghai was approved for listing in late 2019, in Ida There was no variety of sodium chloride injections before the lafon injection was focused on monitoring, so there is some rationality for Idala sodium chloride injections to be included in the medicare form review list, but what we need to do is to reasonably track the injection of Ida la sodium chloride, once the drug dosage is too high or serious adverse reactions, then it should be restricted to use.
    according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme, the schedule for the adjustment of the health insurance catalogue is divided into five phases: the preparation phase (July-August 2020), the filing phase (August-September 2020), Expert review phase (September-October 2020), negotiation and bidding phase (October-November 2020) and announcement results phase (November-December 2020).
    medical insurance adjustment drug preliminary examination list, for the selection of the catalog, immediately into pharmacy (including pharmacoeconomics), clinical medicine and medical insurance expert review stage.
    2020 medical insurance in the first instance of drugs, if successfully through expert review, into the stage of health insurance negotiations, for pharmaceutical companies will be a "big test."
    751 drugs announced at the same time, the complexity of itself is controversial, and later will face price reduction negotiations, how many varieties will laugh to the end, successful finalists? See.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.